Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
出版年份 2022 全文链接
标题
Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-01-14
DOI
10.3389/fimmu.2021.756583
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
- (2021) Cristina Ferrari et al. Journal of Personalized Medicine
- Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
- (2020) David J. Straus et al. BLOOD
- Tislelizumab: First Approval
- (2020) Arnold Lee et al. DRUGS
- Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)
- (2020) Adam Gibb et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
- (2019) Jeffrey P. Sharman et al. INVESTIGATIONAL NEW DRUGS
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
- (2019) Theodoros P. Vassilakopoulos et al. Cancers
- Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
- (2019) Yuqin Song et al. LEUKEMIA
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
- (2019) Basem M. William et al. BLOOD
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
- (2018) Yucai Wang et al. Journal of Hematology & Oncology
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
- (2017) Gary X. Wang et al. RADIOGRAPHICS
- False-Positive 18F-FDG PET/CT Imaging
- (2016) Evangelia Skoura et al. CLINICAL NUCLEAR MEDICINE
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
- (2014) M. D. Gandhi et al. BLOOD
- Lenalidomide and Chronic Lymphocytic Leukemia
- (2013) Ana Pilar González-Rodríguez et al. Biomed Research International
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
- (2012) Nina D. Wagner-Johnston et al. LEUKEMIA & LYMPHOMA
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
- (2011) Asher A. Chanan-Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide-induced tumour flare reaction in mantle cell lymphoma
- (2010) Heather E. Eve et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
- (2010) Asher Chanan-Khan et al. CANCER
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2010) Christine I. Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma
- (2009) Gaetano Corazzelli et al. AMERICAN JOURNAL OF HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now